A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford UniversityThe National Institutes of HealthLeibniz Institute on Aging – Fritz Lipmann Institute (FLI)Ludwig-Maximilians-Universität MünchenWhitehead Institute for Biomedical ResearchUniversity of Virginia School of Medicine and David Sabatini!

Full article on nature.com

carbohyde blog, rare disease